Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04896008
Registration number
NCT04896008
Ethics application status
Date submitted
13/05/2021
Date registered
21/05/2021
Titles & IDs
Public title
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality
Query!
Secondary ID [1]
0
0
A011-14
Query!
Secondary ID [2]
0
0
7962-006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ZENITH
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cardiovascular
0
0
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sotatercept
Other interventions - Placebo
Placebo comparator: Placebo plus background PAH therapy - Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy
Experimental: Sotatercept plus background PAH therapy - Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy
Treatment: Drugs: Sotatercept
Sotatercept is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Other interventions: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to First Confirmed Morbidity or Mortality Event
Query!
Assessment method [1]
0
0
Events are defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of = 24 hours. All events will be adjudicated by a blinded, independent committee of clinical experts.
Query!
Timepoint [1]
0
0
Up to approximately 43 months
Query!
Secondary outcome [1]
0
0
Overall survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from randomization to death due to any cause.
Query!
Timepoint [1]
0
0
Up to approximately 43 months
Query!
Secondary outcome [2]
0
0
Transplant-Free Survival
Query!
Assessment method [2]
0
0
Transplant-free survival is defined as the time from randomization to the first lung transplantation or death due to any cause.
Query!
Timepoint [2]
0
0
Up to approximately 43 months
Query!
Secondary outcome [3]
0
0
Percentage of Participants Who Experienced a Mortality Event
Query!
Assessment method [3]
0
0
Mortality event is defined as death due to any cause throughout the study.
Query!
Timepoint [3]
0
0
Up to approximately 43 months
Query!
Secondary outcome [4]
0
0
Change From Baseline in REVEAL Lite 2 Risk Score at Week 24
Query!
Assessment method [4]
0
0
The REVEAL Lite 2 uses renal insufficiency (by estimated glomerular filtration rate (eGFR)), World Health Organization (WHO) functional class (FC), systolic blood pressure (SBP) and heart rate, 6-Minute Walk Distance (6-MWD), and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) to determine the total risk score. The scores (range: 1-14) can be defined as: low risk as a score of =5, intermediate risk as a score of 6 or 7, and high risk as a score of =8 for the survival rates.
Query!
Timepoint [4]
0
0
Baseline and Week 24
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving a Low or Intermediate (=7) REVEAL Lite 2 Risk Score at Week 24
Query!
Assessment method [5]
0
0
The REVEAL Lite 2 uses renal insufficiency (eGFR), WHO FC, SBP and heart rate, 6-MWD, and NT-proBNP to determine the total risk score. The scores (range: 1-14) can be defined as: low risk as a score of =5, intermediate risk as a score of 6 or 7, and high risk as a score of =8 for the survival rates.
Query!
Timepoint [5]
0
0
Week 24
Query!
Secondary outcome [6]
0
0
Change From Baseline in NT-proBNP levels at Week 24
Query!
Assessment method [6]
0
0
Blood samples will be collected at baseline and at Week 24 to measure NT-proBNP levels.
Query!
Timepoint [6]
0
0
Baseline and Week 24
Query!
Secondary outcome [7]
0
0
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24
Query!
Assessment method [7]
0
0
mPAP was measured by right heart catheterization (RHC) at baseline and at Week 24. mPAP is a hemodynamic parameter used to diagnose PAH.
Query!
Timepoint [7]
0
0
Baseline and Week 24
Query!
Secondary outcome [8]
0
0
Change From Baseline in Pulmonary Vascular Resistance (PVR)
Query!
Assessment method [8]
0
0
PVR is a hemodynamic variable measured by RHC at baseline and at Week 24.
Query!
Timepoint [8]
0
0
Baseline and Week 24
Query!
Secondary outcome [9]
0
0
Percentage of Participants Who Improve in WHO FC
Query!
Assessment method [9]
0
0
The severity of an individual's PAH symptoms was graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC is classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC.
Query!
Timepoint [9]
0
0
Up to approximately 43 months
Query!
Secondary outcome [10]
0
0
Change From Baseline in 6-MWD at Week 24
Query!
Assessment method [10]
0
0
6-MWD is a measure of exercise capacity.
Query!
Timepoint [10]
0
0
Baseline and Week 24
Query!
Secondary outcome [11]
0
0
Change From Baseline in Cardiac Output (CO) at Week 24
Query!
Assessment method [11]
0
0
CO is the volume of blood pumped by the heart per minute.
Query!
Timepoint [11]
0
0
Baseline and Week 24
Query!
Secondary outcome [12]
0
0
Change From Baseline in EuroQoL-5 Dimensions Scale 5 Levels (EQ-5D-5L) Index Score at Week 24
Query!
Assessment method [12]
0
0
EQ-5D-5L measures health outcome. It consists of of descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L system has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses will be used to generate an index score.
Query!
Timepoint [12]
0
0
Baseline and Week 24
Query!
Eligibility
Key inclusion criteria
* Documented diagnostic right heart catheterization prior to screening confirming the diagnosis of World Health Organization (WHO) pulmonary arterial hypertension (PAH) Group 1 in any of the following subtypes:
* Idiopathic PAH
* Heritable PAH
* Drug/toxin-induced PAH
* PAH associated with connective tissue diseases (CTD)
* PAH associated with simple, congenital systemic to pulmonary shunts at least 1 year following repair
* Symptomatic PAH classified as WHO functional class (FC) III or IV
* Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 risk score of =9
* Right heart catheterization performed during screening (or within 2 weeks prior to screening, if done at the clinical study site) documenting a minimum pulmonary vascular resistance (PVR) of =5 Wood units and a pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of =15 mmHg
* Clinically stable and on stable doses of maximum tolerated (per investigator's judgment) double or triple background PAH therapies for at least 30 days prior to screening
* Females of childbearing potential must:
* Have 2 negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy; must agree to ongoing urine or serum pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug
* If sexually active with a male partner, have used, and agree to use highly effective contraception without interruption per protocol; for at least 28 days prior to starting the investigational product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
* Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
* Male participants must:
* Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
* Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
* Ability to adhere to study visit schedule and understand and comply with all protocol requirements
* Ability to understand and provide written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Diagnosis of pulmonary hypertension (PH) WHO Groups 2, 3, 4, or 5
* Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus-associated PAH and PAH associated with portal hypertension
* Diagnosis of pulmonary veno-occlusive diseases or pulmonary capillary hemangiomatosis or overt signs of capillary and/or venous involvement
* Hemoglobin at screening above gender-specific upper limit of normal (ULN), per local laboratory test
* Baseline platelet count <50,000/mm3 (<50.0 x 109/L) at screening
* Baseline systolic blood pressure <85 mmHg at screening
* Pregnant or breastfeeding women
* Serum alanine aminotransferase or aspartate aminotransferase levels or total bilirubin >3.0×ULN
* Currently enrolled in or have completed any other investigational product study within 30 days for small molecule drugs or within 5 half-lives for biologics prior to the date of signed informed consent
* Prior exposure to sotatercept or known allergic reaction to sotatercept, its excipients or luspatercept
* History of pneumonectomy
* Untreated more than mild obstructive sleep apnea
* History of known pericardial constriction
* History of restrictive or congestive cardiomyopathy
* Electrocardiogram (ECG) with Fridericia's corrected QT interval (QTcF) >500 ms during the screening period
* Personal or family history of long QT syndrome or sudden cardiac death
* Left ventricular ejection fraction <45% on historical echocardiogram within 1 year prior to the screening visit
* Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) in the past 6 months prior to the screening visit
* Cerebrovascular accident within 3 months prior to the screening visit
* Significant (= 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
* Currently on dialysis or anticipated need for dialysis within the next 12 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
28/11/2025
Query!
Actual
Query!
Sample size
Target
166
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
St Vincent's Hospital Sydney ( Site 1102) - Darlinghurst
Query!
Recruitment hospital [2]
0
0
John Hunter Hospital ( Site 1101) - New Lambton Heights
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2305 - New Lambton Heights
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nebraska
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Mexico
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Wisconsin
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Bruxelles-Capitale, Region De
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Vlaams-Brabant
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Alberta
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Quebec
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bas-Rhin
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Haute-Garonne
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Meurthe-et-Moselle
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Nord
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Rhone
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Val-de-Marne
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Vienne
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Baden-Wurttemberg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Bayern
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Hessen
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Niedersachsen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Nordrhein-Westfalen
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Saarland
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Sachsen
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Haifa
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Lombardia
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Roma
Query!
Country [42]
0
0
Mexico
Query!
State/province [42]
0
0
Distrito Federal
Query!
Country [43]
0
0
Mexico
Query!
State/province [43]
0
0
Nuevo Leon
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Noord-Holland
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Madrid
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Cambridgeshire
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
London, City Of
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung transplantation, or PAH worsening-related hospitalization of =24 hours, in participants with World Health Organization (WHO) functional class (FC) III or FC IV PAH at high risk of mortality.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04896008
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://engagezone.msd.com/ds_documentation.php
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04896008